# EDGAR Filing Document

**Accession Number:** 0001757499
**File Stem:** 0001493152-23-002868
**Filing Date:** 2023-1
**Character Count:** 3416
**Document Hash:** e3ac9ccb5151944ca14902149c592691
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001493152-23-002868.hdr.sgml**: 20230302

**ACCESSION NUMBER**: 0001493152-23-002868

**CONFORMED SUBMISSION TYPE**: CORRESP

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20230130

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Shuttle Pharmaceuticals Holdings, Inc.
- **CENTRAL INDEX KEY:** 0001757499
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** CORRESP

**BUSINESS ADDRESS:**
- **STREET 1:** ONE RESEARCH COURT
- **STREET 2:** SUITE 450
- **CITY:** ROCKVILLE
- **STATE:** MD
- **ZIP:** 20850
- **BUSINESS PHONE:** 2404034212

**MAIL ADDRESS:**
- **STREET 1:** ONE RESEARCH COURT
- **STREET 2:** SUITE 450
- **CITY:** ROCKVILLE
- **STATE:** MD
- **ZIP:** 20850

January 30, 2023

 ****

***Via EDGAR***

U.S. Securities and Exchange Commission

Division of Corporation Finance

Office of Life Sciences

100 F Street, N.E.

Washington, D.C. 20549-3720

Attention: Daniel Crawford

---

| | |
|:---|:---|
| **Re:** | **Shuttle Pharmaceuticals Holdings, Inc.** |
|  | **Registration Statement on Form S-1** |
|  | **File No. 333-269414** |

---

**Acceleration Request**

---

| | |
|:---|:---|
| **Requested Date:** | **February 1, 2023** |
| **Requested Time:** | **9:00 AM Eastern Time** |

---

Ladies and Gentlemen:

Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, Shuttle Pharmaceuticals Holdings, Inc. (the "Registrant") hereby requests acceleration of the effective date of its Registration Statement on Form S-1 (File No. 333-269414), as amended (the "Registration Statement"), so that it may become effective at 9:00 a.m. Eastern Daylight Time on Friday, February 1, 2023, or as soon as practicable thereafter.

The Registrant hereby acknowledges that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) should the Securities and Exchange Commission (the "Commission") or the staff, acting pursuant to delegated authority, declare the Registration Statement effective, it does not foreclose the Commission from taking any action with respect to the Registration Statement;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the Registration Statement effective, does not relieve the Registrant from its full responsibility for the adequacy and accuracy of the disclosure in the Registration Statement; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) the Registrant may not assert comments of the Commission or the staff and the declaration of effectiveness of the Registration Statement as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.

We request that we be notified of such effectiveness by telephone call to our counsel, Megan J. Penick, of Michelman & Robinson, LLP, at 646-320-4104.

---

| | |
|:---|:---|
| Very truly yours, | Very truly yours, |
| SHUTTLE PHARMACEUTICALS HOLDINGS, INC. | SHUTTLE PHARMACEUTICALS HOLDINGS, INC. |
| By: | */s/ Anatoly Dritschilo* |
|  | Anatoly Dritschilo, M.D. |
|  | Chief Executive Officer |

---

cc: Megan J. Penick, Esq., <br> Michelman & Robinson, LLP